Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Shell PLC (SHEL) Price & Performance

BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Shell PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Shell PLC trades at $90.52 (market cap $250.44B). The key difference: Shell PLC is far larger — about 15.3× BridgeBio Pharma Inc's market cap, and Shell PLC pays a 3.45% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOSHEL
Market Cap
$16.36B$250.44B
Sector
HealthEnergy
52-Week High
$90.17$94.15
52-Week Low
$47.29$70.31
Enterprise Value
$18.14B$292.14B
Dividend Yield
3.45%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Shell PLC

Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.

Read more on SHEL